Eli Lilly’s share price has recovered more than 15% from its late-December pullback and is approaching a technical buy point identified by several Wall Street chart analysts. Over the past six weeks, trading volume has risen by roughly 25%, suggesting renewed institutional interest. This rebound follows a stretch in which the shares underperformed the broader healthcare sector by nearly 8%. Technical strategists note that a sustained move above the 50-day moving average could trigger additional inflows from trend-following funds.

In late January, Eli Lilly announced a collaboration with Nvidia to deploy artificial-intelligence models in early-stage drug discovery. Under the agreement, Lilly will access Nvidia’s flagship GPU clusters and specialized AI software to accelerate target identification and compound optimization. Company executives project that integrating machine-learning algorithms could shorten preclinical timelines by up to 20%, potentially saving hundreds of millions of dollars in R&D expenses over the next five years.

Building on the success of its weekly injectable GLP-1 therapy, Eli Lilly is preparing to launch an oral obesity treatment later this year. In December, management disclosed positive phase 3 maintenance data showing that patients who switched from injection to pill maintained over 85% of their initial weight loss at 24 weeks. The introduction of a once-daily oral option aims to capture an estimated 30% of the addressable U.S. obesity market, which analysts forecast could reach $25 billion in annual sales by 2030.

Eli Lilly delivered a 39% total return in 2025, driven by blockbuster demand for its dual-action metabolic therapy. Revenue from its obesity franchise more than doubled year-over-year, contributing over $8 billion in incremental sales. Looking ahead, management reiterated guidance for mid-teens revenue growth in 2026, supported by planned label expansions, broader insurance coverage including the first-ever Medicare benefit for obesity drugs, and ongoing pipeline readouts in diabetes and autoimmune indications.